Additionally, we found that interferon-gamma and interleukin-2 receptor subunit β were linked to a reduced risk of CRC, suggesting that therapeutic agents targeting these molecules could be promising options in the treatment of colorectal cancer. This evidence concerns the gene IFNG and colorectal cancer.